---
schema_version: "secwatch.filing_event.v1"
accession: "0001513162-21-000162"
form_type: "8-K"
ticker: "BMRA"
cik: "0000073290"
company_name: "BIOMERICA INC"
filed_at: "2021-12-16T23:59:59+00:00"
generated_at: "2026-06-28T00:42:02.851735+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biomerica preliminary Q2 revenue $4.6M (+238% YoY); backlog $4M; InFoods trial data due Jan 2022

## Summary
- Revenue approximately $4.6M for Q2 ended Nov 30, 2021, up 238% from $1.4M a year ago, driven by COVID test demand.
- Operating loss expected between $0.9M and $1.3M; logistics constraints and higher shipping costs hurt margins.
- Backlog of unfilled orders exceeds $4.0M entering Q3; cash balance over $7M, partly from prepayments.
- InFoods IBS clinical trial data collection complete; topline results expected by end of January 2022.

## SEC filing metadata
- accession: 0001513162-21-000162
- form_type: 8-K
- ticker: BMRA
- cik: 0000073290
- company_name: BIOMERICA INC
- filed_at: 2021-12-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/73290/000151316221000162/0001513162-21-000162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/73290/000151316221000162/bmra-20211216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001513162-21-000162
- JSON: https://secwatch.observer/filing/0001513162-21-000162.json
- Plain text: https://secwatch.observer/filing/0001513162-21-000162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.